A 2022 study involving people with Irritable Bowel Syndrome (IBS) found that ROSE 010, a GLP-1 receptor agonist, reduced IBS pain during flare-ups, primarily in female participants
When analyzed by individual agents, liraglutide demonstrated the strongest protective association (OR = 0.13, 95% CI: 0.050.32, p = 0.0001), followed by dulaglutide (OR = 0.26, 95% CI: 0.11-0.60, p = 0.01) and semaglutide (OR = 0.27, 95% CI: 0.080.98, p = 0.046), all of which were statistically significant
Effectiveness: Injections appear to be more effective overall
Aim for 99% purity by HPLC on a batch-specific, third-party COA
It has seen successful clinical trials with better weight loss and metabolic health outcomes than placebo and single action drugs
The early publication of the study abstract on 22 September 2023 was released ahead of its planned publication at the annual meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany, in early October 2023